<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01267695</url>
  </required_header>
  <id_info>
    <org_study_id>WJP-320.6700.09010</org_study_id>
    <nct_id>NCT01267695</nct_id>
  </id_info>
  <brief_title>Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor</brief_title>
  <official_title>Perioperative Imatinib Mesylate in Treating Patients With Locally Advanced Gastrointestinal Stromal Tumor</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Peking University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Peking University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Imatinib mesylate may stop the growth of tumor cells by blocking some of the enzymes needed&#xD;
      for cell growth. Perioperative imatinib mesylate may shrink the tumor and may reduce the&#xD;
      chance of relapse after surgery. This phase II trial is studying the effectiveness of&#xD;
      perioperative imatinib mesylate in treating patients with locally advanced gastrointestinal&#xD;
      stromal tumor.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Open-label trial in patients with locally advanced GISTs admitted to Department of Surgery,&#xD;
      Beijing Cancer Hospital and Institute between April 2010 and May 2013 was carried out&#xD;
      prospectively. Patients were planned to be treated with imatinib for duration of 6 months&#xD;
      followed by surgical resection. Postoperative imatinib was planned to be administrated for&#xD;
      1.5 years. The primary end point was recurrent free survival (RFS) at 2 years; the secondary&#xD;
      end points included objective response rate (ORR), surgical outcomes and drug safety.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">October 2014</completion_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of disease recurrence at 2 years</measure>
    <time_frame>4 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rates of objective response (complete, partial, and stable)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determine the safety and tolerability of this drug in these patients.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">20</enrollment>
  <condition>Gastrointestinal Stromal Tumor</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>imatinib mesylate</intervention_name>
    <description>Patients receive oral imatinib mesylate once daily for 6 months in the absence of disease progression or unacceptable toxicity. Patients with disease progression or unacceptable toxicity are considered for immediate surgical resection. Within 2-6 weeks after completion of imatinib mesylate, patients with responding or stable disease undergo surgical resection. Two to four weeks after surgery, patients receive oral imatinib mesylate once daily for one and a half years.</description>
    <other_name>Gleevec</other_name>
    <other_name>STI-571</other_name>
    <other_name>NSC #716051</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>conventional surgery</intervention_name>
    <description>All the patients should receive elective surgery with R0 resection.</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria:&#xD;
&#xD;
          -  DISEASE CHARACTERISTICS:&#xD;
&#xD;
               -  Histologically confirmed gastrointestinal stromal tumor&#xD;
&#xD;
                    -  Locally advanced disease: tumour size &gt;5 cm and mitotic count &gt;5/HPF; tumour&#xD;
                       size &gt;10 cm; mitotic count &gt;10/HPF&#xD;
&#xD;
                    -  Potentially resectable disease: Multivisceral resection may be necessary to&#xD;
                       get sufficient margins&#xD;
&#xD;
               -  Documented c-kit (CD117) expression by immunohistochemical analysis of either&#xD;
                  initial core specimen or, if recurrent disease, from original tumor block&#xD;
&#xD;
               -  At least 1 site of measurable disease&#xD;
&#xD;
               -  No known brain metastases&#xD;
&#xD;
          -  PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age:18 and over Performance status:ECOG 0-3 Life expectancy:Not specified&#xD;
&#xD;
          -  Platelet count &gt; 100,000/mm3&#xD;
&#xD;
          -  Absolute neutrophil count &gt; 1,500/mm3 Hepatic&#xD;
&#xD;
          -  AST and ALT &lt; 2.5 times upper limits of normal (ULN) (5 times ULN if hepatic&#xD;
             metastases are present)&#xD;
&#xD;
          -  Bilirubin &lt; 1.5 times ULN&#xD;
&#xD;
          -  No chronic active hepatitis&#xD;
&#xD;
          -  No cirrhosis&#xD;
&#xD;
          -  No other chronic liver disease Renal&#xD;
&#xD;
          -  Creatinine &lt; 1.5 times ULN&#xD;
&#xD;
          -  No chronic renal disease Cardiovascular&#xD;
&#xD;
          -  No New York Heart Association class III-IV cardiac disease&#xD;
&#xD;
          -  No congestive heart failure&#xD;
&#xD;
          -  No myocardial infarction within the past 6 months Immunology&#xD;
&#xD;
          -  No active uncontrolled infection&#xD;
&#xD;
          -  No known HIV positivity Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective barrier contraception during and for 3 months&#xD;
             after completion of study treatment&#xD;
&#xD;
          -  Must be medically fit to undergo surgery&#xD;
&#xD;
          -  No other primary malignancy within the past 5 years except basal cell skin cancer,&#xD;
             carcinoma in situ of the cervix, or a primary malignancy that is not currently&#xD;
             clinically significant and does not require active intervention&#xD;
&#xD;
          -  No gastrointestinal obstruction or major bleeding episode requiring immediate surgical&#xD;
             intervention&#xD;
&#xD;
          -  No uncontrolled diabetes&#xD;
&#xD;
          -  No other severe or uncontrolled medical disease&#xD;
&#xD;
          -  No significant history of noncompliance to medical regimens&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No concurrent anticancer biologic agents&#xD;
&#xD;
          -  More than 4 weeks since prior chemotherapy (6 weeks for nitrosourea or mitomycin)&#xD;
             unless disease is rapidly progressing&#xD;
&#xD;
          -  No concurrent anticancer chemotherapy&#xD;
&#xD;
          -  At least 28 days since prior radiotherapy&#xD;
&#xD;
          -  More than 2 weeks since prior major surgery except tumor biopsy Other&#xD;
&#xD;
          -  At least 28 days since prior investigational drugs&#xD;
&#xD;
          -  At least 28 days since prior imatinib mesylate&#xD;
&#xD;
          -  No concurrent therapeutic doses of warfarin&#xD;
&#xD;
          -  Concurrent low-molecular weight heparin or mini-dose warfarin (1 mg per day)&#xD;
             prophylaxis is allowed&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Peking University School of Oncology</name>
      <address>
        <city>Beijing</city>
        <zip>100142</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://www.uptodate.com/patients/content/topic.do?topicKey=~1ahlhQH65OZROGa</url>
    <description>Related Info</description>
  </link>
  <reference>
    <citation>Eisenberg BL, Harris J, Blanke CD, Demetri GD, Heinrich MC, Watson JC, Hoffman JP, Okuno S, Kane JM, von Mehren M. Phase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665. J Surg Oncol. 2009 Jan 1;99(1):42-7. doi: 10.1002/jso.21160.</citation>
    <PMID>18942073</PMID>
  </reference>
  <reference>
    <citation>Seshadri RA, Rajendranath R. Neoadjuvant imatinib in locally advanced gastrointestinal stromal tumors. J Cancer Res Ther. 2009 Oct-Dec;5(4):267-71. doi: 10.4103/0973-1482.59905.</citation>
    <PMID>20160360</PMID>
  </reference>
  <reference>
    <citation>Saied GM, Kensarah AM. Six months neoadjuvant imatinib improves resectability potential of gastric stromal tumors in Egyptian patients. Int J Surg. 2010;8(2):105-8. doi: 10.1016/j.ijsu.2009.09.016. Epub 2009 Nov 24.</citation>
    <PMID>19944196</PMID>
  </reference>
  <reference>
    <citation>Machlenkin S, Pinsk I, Tulchinsky H, Ziv Y, Sayfan J, Duek D, Rabau M, Walfisch S. The effect of neoadjuvant Imatinib therapy on outcome and survival after rectal gastrointestinal stromal tumour. Colorectal Dis. 2011 Oct;13(10):1110-5. doi: 10.1111/j.1463-1318.2010.02442.x.</citation>
    <PMID>21040362</PMID>
  </reference>
  <verification_date>February 2015</verification_date>
  <study_first_submitted>December 27, 2010</study_first_submitted>
  <study_first_submitted_qc>December 27, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 28, 2010</study_first_posted>
  <last_update_submitted>February 2, 2015</last_update_submitted>
  <last_update_submitted_qc>February 2, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Peking University</investigator_affiliation>
    <investigator_full_name>Ziyu Li</investigator_full_name>
    <investigator_title>vice director of Department of Gastrointestinal Surgeryï¼ŒPeking University Cancer Hospital and Institute</investigator_title>
  </responsible_party>
  <keyword>Gastrointestinal Stromal Tumor</keyword>
  <keyword>Imatinib mesylate</keyword>
  <keyword>Perioperative therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastrointestinal Stromal Tumors</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imatinib Mesylate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

